---
title: "Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026 | FLGT Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292237736.md"
description: "Fulgent Genetics, Inc. (NASDAQ: FLGT) announced it will release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will host a conference call at 4:30 PM ET to discuss the results and answer questions. The call can be accessed via live audio webcast on the company's Investor Relations website, with an audio replay available later."
datetime: "2026-07-09T12:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292237736.md)
  - [en](https://longbridge.com/en/news/292237736.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292237736.md)
generator: "portal-rs"
---

# Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026 | FLGT Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location.

**About Fulgent**

Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a diagnostic business into a fully integrated precision medicine company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260709923437/en/

**Investor Relations Contact:**  
The Blueshirt Group  
Lauren Sloane, Lauren@blueshirtgroup.com

Source: Fulgent Genetics, Inc.

### Related Stocks

- [FLGT.US](https://longbridge.com/en/quote/FLGT.US.md)

## Related News & Research

- [Fulgent Genetics Q2 revenue rises 20% sequentially, sees billing system transition delay](https://longbridge.com/en/news/294410077.md)
- [Hanlin Gao Sells 1,673 Shares of Fulgent Genetics (NASDAQ:FLGT) Stock](https://longbridge.com/en/news/298031252.md)
- [Nebius COO Nave Ophir disposes of USD 113.38 million in Class A shares](https://longbridge.com/en/news/301073075.md)
- [Personalis-Tempus AI deal clears US antitrust waiting period under HSR Act](https://longbridge.com/en/news/301072040.md)
- [LIVE MARKETS-TSMC earnings could cause another round of consensus upgrades](https://longbridge.com/en/news/301145455.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**